Constraining FGFR pathways by a selective FGFR inhibitor (FGFRi) Erdafitinib significantly suppressed tumor growth with increased CD3+ (CD4+ and CD8+) T cell infiltration in immunocompetent BALB/c mice bearing EMT6 or 4T1 tumors (Figure 2A-E, Figure S2A). The gene discussed is CD4; the disease is neoplasm.